Autolus Therapeutics plc

NASDAQ:AUTL

Biotechnology

Healthcare
$1.06 +0.33%

+$0.01 today

Market cap
$282.13M
Beta
2.01
P/E (TTM)
-1.4
EPS (TTM)
-$1.09
52W Low $1.18High $2.70

Volume 2.56M

Average 1.60M

AUTL Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Autolus Therapeutics plcNASDAQ: AUTL

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$1.46B, compared with -$1.17B a year earlier.

Context

  • Retained earnings amounted to 276.7% of total assets at the end of Q1 FY2026, up 120.0 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -24.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.46B-5.2% QoQ
Last fiscal yearDec 2025
-$1.39B-26.2% YoY
Year agoMar 2025
-$1.17B-24.7% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.7%——
1 year-26.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(1.39B) USD
Year-over-year change
-26.2%

Retained Earnings vs competitors

How AUTL compares with its peers on the latest reported figures

  • AUTL's Mar 2026 retained earnings of -$1.46B is the 5th highest of the 10 companies compared; the peer median is -$1.57B.
  • Its year-over-year change of -24.7% is the 9th highest of 10, against a peer median of -9.0%.
  • Retained earnings amounts to 276.7% of total assets for AUTL, versus a peer median of 417.2%.
AUTL Competitors Peer median
Retained Earnings for AUTL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CLLSCellectis S.A.Mar 2026-$351.94M -1.2%—121.7%
DTILPrecision BioSciences, Inc.Mar 2026-$546.63M -8.7%—379.9%
CRBUCaribou Biosciences, Inc.Mar 2026-$621.6M -27.3%—417.2%
IPSCCentury Therapeutics, Inc.Mar 2026-$813.56M -15.3%—249.1%
AUTLAutolus Therapeutics plcMar 2026-$1.46B -24.7%—276.7%
FATEFate Therapeutics, Inc.Mar 2026-$1.57B -9.0%—549.5%
LYELLyell Immunopharma, Inc.Mar 2026-$1.64B -17.6%—468.8%
LEGNLegend Biotech CorporationSep 2026-$1.93B -0.0%—114.7%
ATRAAtara Biotherapeutics, Inc.Mar 2026-$2.03B -0.5%—10131.6%
ALLOAllogene Therapeutics, Inc.Mar 2026-$2.05B -9.2%—518.6%
Peer median (excluding AUTL) -$1.57B-9.0%—417.2%

Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents310.34M382.44M239.57M227.38M104.13M
Short-term Investments000360.64M196.58M
Net Receivables68K28.98M1.05M48.24M75.79M
Inventory0004.14M33.21M
Other Current Assets27.83M2.02M26.05M5.32M4.93M
Total Current Assets346.95M425.77M275.3M660.93M435.92M
Property, Plant & Equipment (Net)52.32M58.42M95.65M105.05M128.5M
Goodwill00000
Intangible Assets65K0012.37M19.81M
Long-term Investments00000
Tax Assets02.08M3.06M3.24M3.56M
Other Non-current Assets6.23M4.01M1.36M1.13M1.28M
Total Non-current Assets58.61M64.5M100.08M121.8M153.15M
Total Assets405.56M490.27M375.38M782.73M589.07M
Account Payables431K531K103K1.97M3.08M
Short-term Debt000014.57M
Tax Payables0003.59M0
Deferred Revenue00000
Other Current Liabilities160K10.57M15.29M23.66M55.79M
Total Current Liabilities28.55M46.37M44.74M60.74M73.44M
Long-term Debt47.02M000270.2M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities128K126.02M171.26M245.03M477K
Total Non-current Liabilities63.69M145.23M219.17M294.66M337.5M
Total Liabilities92.24M191.6M263.91M355.4M410.94M
Common Stock4K8K8K12K12K
Retained Earnings(521.34M)(670.18M)(878.56M)(1.1B)(1.39B)
Accumulated OCI(8.45M)(38.9M)(28.99M)(29.17M)(5.36M)
Other Stockholders Equity(1)118K118K118K0
Minority Interest00000
Total Equity313.32M298.67M111.47M427.33M178.13M
Total Debt68.01M24.26M52.97M52.63M351.59M
Net Debt(242.32M)(358.18M)(186.6M)(174.75M)247.45M

Autolus Therapeutics plc

NASDAQ:AUTL

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.